MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
ProQR Therapeutics N.V. Market Cap 2011-2026 | PRQR
As of April 13, 2026 ProQR Therapeutics N.V. has a market cap of $ 99.5 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap ProQR Therapeutics N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 68.7 M | 188 M | 291 M | 454 M | 85 M | 96.9 M | 123 M | 223 M | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 454 M | 68.7 M | 191 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 7.92 | -0.94 % | $ 78.3 M |  USA |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Precision BioSciences
DTIL
|
49.9 M | $ 6.73 | 0.9 % | $ 25.9 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
561 M | $ 2.15 | -0.69 % | $ 447 M | USA |
 |
Evogene Ltd.
EVGN
|
66.3 M | $ 0.81 | -0.33 % | $ 27.9 M |  Israel |
 |
BioNTech SE
BNTX
|
62.9 B | $ 97.86 | 2.47 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 20.29 | -0.39 % | $ 948 M | USA |
 |
Galectin Therapeutics
GALT
|
178 M | $ 2.42 | 5.22 % | $ 155 M | USA |
 |
Genmab A/S
GMAB
|
25 B | $ 28.24 | -0.04 % | $ 18 B |  Danmark |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Grifols, S.A.
GRFS
|
8.42 B | $ 8.14 | -0.85 % | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
GT Biopharma
GTBP
|
2.59 M | $ 0.36 | -3.5 % | $ 1.98 M | USA |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 67.79 | -0.05 % | $ 8.12 B | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.42 | 1.07 % | $ 365 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 2.96 | 1.37 % | $ 4.87 M | Israel |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.15 | 1.72 % | $ 444 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 24.3 | 0.37 % | $ 3.09 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 28.82 | -0.24 % | $ 1.66 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 32.37 | 0.4 % | $ 2.15 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.52 | 1.68 % | $ 405 M | Britain |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | USA |
 |
ImmuCell Corporation
ICCC
|
58 M | $ 7.24 | 2.33 % | $ 65.3 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
|
Immatics N.V.
IMTX
|
503 M | $ 10.61 | 1.73 % | $ 668 M | Germany |
 |
Incyte Corporation
INCY
|
19.5 B | $ 96.66 | 0.61 % | $ 18.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.58 | 1.18 % | $ 16.2 M | USA |
 |
InflaRx N.V.
IFRX
|
149 M | $ 1.05 | 4.95 % | $ 152 M | Germany |